Cargando…

Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled, phase I clinical trial

Detalles Bibliográficos
Autores principales:	Wang, Guiqiang, Zhao, Kexin, Han, Jun, Hu, Zhongyu, Zhang, Tianzuo, Wang, Yanchao, Shi, Rui, Li, Yanhua, Song, Qinqin, Du, Haijun, He, Peng, Xu, Shuping, Yang, Xinjie, Fu, Yongpan, Cui, Yimin, Xie, Liangzhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Infection Association. Published by Elsevier Ltd. 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672836/ https://www.ncbi.nlm.nih.gov/pubmed/36403700 http://dx.doi.org/10.1016/j.jinf.2022.11.008

Ejemplares similares

Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C in adults previously vaccinated with inactivated vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trial
por: Hannawi, Suad, et al.
Publicado: (2022)

Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trial
por: Hannawi, Suad, et al.
Publicado: (2022)

A Polysaccharide-RBD-Fc-Conjugated COVID-19 Vaccine, SCTV01A, Showed High Immunogenicity and Low Toxicity in Animal Models
por: Sun, Chunyun, et al.
Publicado: (2023)

Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men
por: Hannawi, Suad, et al.
Publicado: (2023)

SCTV-UNet: a COVID-19 CT segmentation network based on attention mechanism
por: Liu, Xiangbin, et al.
Publicado: (2023)

Nonameric structures of the cytoplasmic domain of FlhA and SctV in the context of the full-length protein
por: Kuhlen, Lucas, et al.
Publicado: (2021)

Safety, Tolerability, and Immunogenicity of COVID-19 Bivalent Vaccination
por: Saxena, Divyasha, et al.
Publicado: (2023)

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Monoclonal Antibody (SCTA01) Targeting SARS-CoV-2 in Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, Phase I Study
por: Li, Yinjuan, et al.
Publicado: (2021)

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2023)

Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2022)

A Randomized, Placebo-Controlled Trial Evaluating Safety and Immunogenicity of the Killed, Bivalent, Whole-Cell Oral Cholera Vaccine in Ethiopia
por: Desai, Sachin N., et al.
Publicado: (2015)

The Role of the Membrane-Associated Domain of the Export Apparatus Protein, EscV (SctV), in the Activity of the Type III Secretion System
por: Mitrović, Boško, et al.
Publicado: (2021)

Crystals of SctV from different species reveal variable symmetry for the cytosolic domain of the type III secretion system export gate
por: Gilzer, Dominic, et al.
Publicado: (2022)

532. Nirmatrelvir/Ritonavir Versus Placebo in Unvaccinated and Vaccinated High Risk Patients
por: Leister-Tebbe, Heidi, et al.
Publicado: (2023)

Immunogenicity of a Bivalent Non-Purified Recombinant Vaccine against Botulism in Cattle
por: Moreira, Clóvis, et al.
Publicado: (2018)

Immunogenicity of Bivalent Omicron BA.4/5–Adapted Vaccine in Hemodialysis Patients
por: Anft, Moritz, et al.
Publicado: (2023)

Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocol
por: Tan, Ngoc H., et al.
Publicado: (2022)

Safety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females
por: Shi, Li-Wei, et al.
Publicado: (2023)

Structure of the cytoplasmic domain of SctV (SsaV) from the Salmonella SPI-2 injectisome and implications for a pH sensing mechanism
por: Matthews-Palmer, Teige R.S., et al.
Publicado: (2021)

Caring for the Unvaccinated
por: Parker, William F.
Publicado: (2022)

Immunogenicity of a Bivalent Adjuvanted Glycoconjugate Vaccine against Salmonella Typhimurium and Salmonella Enteritidis
por: Fiorino, Fabio, et al.
Publicado: (2017)

Trial Evaluation of Protection and Immunogenicity of Piscine Bivalent Streptococcal Vaccine: From the Lab to the Farms
por: Kannika, Korntip, et al.
Publicado: (2022)

Immunogenicity of a bivalent killed thimerosal-free oral cholera vaccine, Euvichol, in an animal model
por: Lee, Eun Young, et al.
Publicado: (2018)

Bivalent Conjugate Vaccine Induces Dual Immunogenic Response That Attenuates Heroin and Fentanyl Effects in Mice
por: Barrientos, Rodell C., et al.
Publicado: (2021)

Mosquirix™ RTS, S/AS01 Vaccine Development, Immunogenicity, and Efficacy
por: Nadeem, Aroosa Younis, et al.
Publicado: (2022)

Managing Unvaccinated Staff
Publicado: (2022)

Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial
por: Zhang, Jikai, et al.
Publicado: (2021)

Immunogenicity Studies of Bivalent Inactivated Virions of EV71/CVA16 Formulated with Submicron Emulsion Systems
por: Lin, Chih-Wei, et al.
Publicado: (2014)

Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines
por: Capeding, Maria Rosario Z., et al.
Publicado: (2017)

LB750. Safety and Immunogenicity of a Bivalent Omicron-Containing Booster Vaccine against COVID-19
por: Chalkias, Spyros, et al.
Publicado: (2022)

A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine
por: Leroux-Roels, Isabel, et al.
Publicado: (2022)

Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial
por: Mo, Zhao-Jun, et al.
Publicado: (2022)

An orienting response is not enough: Bivalency not infrequency causes the bivalency effect
por: Rey-Mermet, Alodie, et al.
Publicado: (2013)

What’s the evidence for fining the unvaccinated?
por: Vogel, Lauren, et al.
Publicado: (2022)

Immunogenicity of Individual Vaccine Components in a Bivalent Nicotine Vaccine Differ According to Vaccine Formulation and Administration Conditions
por: Cornish, Katherine E., et al.
Publicado: (2013)

A bivalent vaccine confers immunogenicity and protection against Shigella flexneri and enterotoxigenic Escherichia coli infections in mice
por: Medeiros, Pedro Henrique Q. S., et al.
Publicado: (2020)

Immunogenicity of a Killed Bivalent (O1 and O139) Whole Cell Oral Cholera Vaccine, Shanchol, in Haiti
por: Charles, Richelle C., et al.
Publicado: (2014)

Immunogenicity of a bivalent protein as a vaccine against Edwardsiella anguillarum and Vibrio vulnificus in Japanese eel (Anguilla japonica)
por: Guo, Songlin, et al.
Publicado: (2018)

Immunogenic Cross-Reactivity between Goose and Muscovy Duck Parvoviruses: Evaluation of Cross-Protection Provided by Mono- or Bivalent Vaccine
por: Palya, Vilmos, et al.
Publicado: (2022)

Immunogenicity and Efficacy of Monovalent and Bivalent Formulations of a Virus-Like Particle Vaccine against SARS-CoV-2
por: Resch, Matthew D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3clpft2jgrmlavf3bcq6iegh72